Literature DB >> 17216652

Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease.

Richard M Camicioli1, Christopher C Hanstock, Thomas P Bouchard, Myrlene Gee, Nancy J Fisher, W R Wayne Martin.   

Abstract

The anterior cingulate (AC) gyrus and the presupplementary motor area (pre-SMA) show pathological changes in Parkinson's disease (PD). We examined if PD patients show magnetic resonance spectroscopy (MRS) changes in NAA/Cr in the AC, pre-SMA, or posterior cingulate (PC). Forty-four (27 male, 17 female) healthy nondemented PD patients and 38 controls (18 male, 20 female) 65 years of age and older were examined using the Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Examination, Frontal Assessment Battery, and Geriatric Depression Scale. MRS was performed at 1.5 T. Voxels (8 cc; PRESS; TE = 80; TR = 1,600 ms) were placed mid-sagittally. Gray matter and white matter volumes were measured within voxels using SPM2. Spectra were analyzed using LC model to yield NAA/Cr and Cho/Cr. Demographic and cognitive measures did not differ between groups. Motor UPDRS was 17.7 +/- 8.8 for PD. Pre-SMA NAA/Cr was lower in PD (PD: 1.39 +/- 0.17; control: 1.47 +/- 0.16; P = 0.045) and correlated negatively with age (r = 0.39; P = 0.01), but not with UPDRS, disease duration, or dopamine equivalents. AC and PC NAA/Cr and Cho/Cr in any region did not differ (P > 0.05). In conclusion, pre-SMA NAA/Cr was selectively decreased in PD, consistent with neuronal dysfunction. This should be further examined as a biomarker of disease in PD.

Entities:  

Mesh:

Year:  2007        PMID: 17216652     DOI: 10.1002/mds.21288

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain.

Authors:  Shane A Perrine; Farhad Ghoddoussi; Mark S Michaels; Elisabeth M Hyde; Donald M Kuhn; Matthew P Galloway
Journal:  Neurotoxicology       Date:  2010-08-26       Impact factor: 4.294

3.  Parkinson's disease and healthy aging: independent and interacting effects on action selection.

Authors:  Laura E Hughes; Roger A Barker; Adrian M Owen; James B Rowe
Journal:  Hum Brain Mapp       Date:  2010-02-16       Impact factor: 5.038

Review 4.  Magnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's Disease.

Authors:  Benito de Celis Alonso; Silvia S Hidalgo-Tobón; Manuel Menéndez-González; José Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Neurol       Date:  2015-07-03       Impact factor: 4.003

Review 5.  Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Authors:  Usman Saeed; Jordana Compagnone; Richard I Aviv; Antonio P Strafella; Sandra E Black; Anthony E Lang; Mario Masellis
Journal:  Transl Neurodegener       Date:  2017-03-28       Impact factor: 8.014

Review 6.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

Review 7.  Targeting mitophagy in Parkinson's disease.

Authors:  Emily H Clark; Aurelio Vázquez de la Torre; Tamaki Hoshikawa; Thomas Briston
Journal:  J Biol Chem       Date:  2020-12-24       Impact factor: 5.157

8.  Differential Changes in Arteriolar Cerebral Blood Volume between Parkinson's Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorder - An Exploratory Study.

Authors:  Adrian G Paez; Chunming Gu; Suraj Rajan; Xinyuan Miao; Di Cao; Vidyulata Kamath; Arnold Bakker; Paul G Unschuld; Alexander Y Pantelyat; Liana S Rosenthal; Jun Hua
Journal:  Tomography       Date:  2020-12

Review 9.  Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?

Authors:  Rosella Ciurleo; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

Review 10.  Current status of biomarker research in neurology.

Authors:  Jiri Polivka; Jiri Polivka; Kristyna Krakorova; Marek Peterka; Ondrej Topolcan
Journal:  EPMA J       Date:  2016-07-04       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.